News Release(2017)

December 6, 2017

Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" Launches in Japan

September 27, 2017

Marketing Approval for Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" was Obtained in Japan

June 9, 2017

Exclusive License Agreement for Avacopan, a selective inhibitor of the Complement C5a Receptor, for Rare Kidney Diseases, in Japan

April 24, 2017

Announcement of the Discontinuation of the Development of KCT-0809, an Anti-Dry Eye Drug

March 13, 2017

Kissei and Maruishi to collaborate for development and sales/marketing of kappa opioid receptor agonist, "MR13A9", in Japan